B(C6F5)3-catalyzed hydrosilylation of cyclicimides afforded an efficient synthetic method of pyrrolidines. In the presence of 5 mol% B(C6F5)3, various aromatic, aliphatic and polycyclic imides were smoothly reduced by PhSiH3 to generate the corresponding pyrrolidines in high yields. The reaction profiles monitored by 1H NMR spectroscopy disclosed the reduction process of cyclicimides and the effect of difference
B(C 6 F 5)3催化的环状酰亚胺的氢化硅烷化提供了吡咯烷的有效合成方法。在5mol%B(C 6 F 5)3的存在下,各种芳族,脂族和多环酰亚胺被PhSiH 3平滑还原,从而以高收率生成相应的吡咯烷。通过1 H NMR光谱监测的反应曲线揭示了环酰亚胺的还原过程以及氢化硅烷的不同结构对氢化硅烷化的影响。
Potassium Hydroxide-Catalyzed Chemoselective Reduction of Cyclic Imides with Hydrosilanes: Synthesis of ω-Hydroxylactams and Lactams
hydroxide‐catalyzed hydrosilylation exhibits excellent activity and chemoselectivity for the reduction of cyclic imides under mild reaction conditions. The chemoselectivity of the reduction system may be readily tuned by changing the identity and stoichiometry of the hydrosilanes: a polymethylhydrosiloxane (PMHS)/potassium hydroxide reduction system resulted in the reduction of various cyclic imides to
Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors
作者:Soo Yei Ho、Jenefer Alam、Duraiswamy Athisayamani Jeyaraj、Weiling Wang、Grace Ruiting Lin、Shi Hua Ang、Eldwin Sum Wai Tan、May Ann Lee、Zhiyuan Ke、Babita Madan、David M. Virshup、Li Jun Ding、Vithya Manoharan、Yun Shan Chew、Choon Bing Low、Vishal Pendharkar、Kanda Sangthongpitag、Jeffrey Hill、Thomas H. Keller、Anders Poulsen
DOI:10.1021/acs.jmedchem.7b00662
日期:2017.8.10
Porcupine is an O-acyltransferase that regulates Wnt secretion. Inhibiting porcupine may block the Wnt pathway which is often dysregulated in various cancers. Consequently porcupine inhibitors are thought to be promising oncology therapeutics. A high throughput screen against porcupine revealed several potent hits that were confirmed to be Wnt pathway inhibitors in secondary assays. We developed a pharmacophore model and used the putative bioactive conformation of a xanthine inhibitor for scaffold hopping. The resulting maleimide scaffold was optimized to subnanomolar potency while retaining good physical druglike properties. A preclinical development candidate was selected for which extensive in vitro and in vivo profiling is reported.